The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells  by Harris, William J. et al.
Cancer Cell
ArticleThe Histone Demethylase KDM1A Sustains
the Oncogenic Potential of MLL-AF9
Leukemia Stem Cells
William J. Harris,1 Xu Huang,1 James T. Lynch,1 Gary J. Spencer,1 James R. Hitchin,2 Yaoyong Li,3 Filippo Ciceri,1
Julian G. Blaser,1 Brigit F. Greystoke,1 Allan M. Jordan,2 Crispin J. Miller,3 Donald J. Ogilvie,2 and Tim C.P. Somervaille1,*
1Cancer Research UK Leukaemia Biology Laboratory
2Cancer Research UK Drug Discovery Unit
3Cancer Research UK Applied Computational Biology and Bioinformatics Group
Paterson Institute for Cancer Research, University of Manchester, Manchester, M20 4BX, United Kingdom
*Correspondence: tsomervaille@picr.man.ac.uk
DOI 10.1016/j.ccr.2012.03.014SUMMARYUsing a mouse model of human MLL-AF9 leukemia, we identified the lysine-specific demethylase KDM1A
(LSD1 or AOF2) as an essential regulator of leukemia stem cell (LSC) potential. KDM1A acts at genomic
loci bound by MLL-AF9 to sustain expression of the associated oncogenic program, thus preventing differ-
entiation and apoptosis. In vitro and in vivo pharmacologic targeting of KDM1A using tranylcypromine
analogs active in the nanomolar range phenocopied Kdm1a knockdown in both murine and primary human
AML cells exhibiting MLL translocations. By contrast, the clonogenic and repopulating potential of normal
hematopoietic stem and progenitor cells was spared. Our data establish KDM1A as a key effector of the
differentiation block in MLL leukemia, which may be selectively targeted to therapeutic effect.INTRODUCTION
Epigenetic dysfunction has a central role in the pathology of
myeloid malignancy. This is illustrated by the discovery of recur-
rently occurring mutations targeting genes that code for epige-
netic regulators, such as the methylcytosine hydroxylase TET2,
DNA methyltransferase DNMT3A, histone H3K27 methyltrans-
ferase EZH2, and Polycomb-related protein ASXL1. Mutations
in IDH1 and IDH2 likely also affect the epigenome through neo-
morphic generation of 2-hydroxyglutarate, which inhibits TET2
and Jumonji-domain histone demethylases. Further, subtypes
of acute myeloid leukemia (AML) exhibit distinct and abnormal
patterns of DNA methylation (reviewed in Fathi and Abdel-
Wahab, 2012).
Novel oncoproteins generated by recurrently occurring
chromosomal translocations in myeloid leukemia also induce
epigenetic dysfunction. For example, the gene coding for theSignificance
Epigenetic therapies hold promise in the treatment of myeloid
ated. Our observations delineate the histone demethylase KD
MLL-associated oncogenic program and cellular oncogenic p
KDM1A abrogate clonogenic potential and induce differentiat
both in vitro and in vivo, while sparing normal repopulating
window. Our data suggest that KDM1A is a candidate target
human myeloid leukemia and mandate evaluation of KDM1A in
malignancy.H3K4 methyltransferase MLL, itself a key epigenetic regulator,
is mutated by translocation in about 4% of human AML. This
results in constitutive transcription at MLL target genes through
aberrant recruitment by MLL fusion partners of proteins and
complexes associated with transcription elongation, including
pTEFb, PAFc, and DOT1L, an H3K79 methyltransferase (Yo-
koyama et al., 2010; Lin et al., 2010; Muntean et al., 2010).
These and other observations have led to speculation that
regulators of the structure and function of chromatin, such as
enzymes that regulate turnover of DNA methylation, histone
methylation, or histone acetylation, might be attractive thera-
peutic targets in myeloid malignancy. To date, only the DNA
demethylating agent azacitidine has provided a survival benefit
in phase III trials in patients with high-risk myelodysplasia
(Fenaux et al., 2009). Although this emphasizes that epigenetic
therapies hold significant potential, it also highlights the neces-
sity for identification and evaluation of other therapeutic targets.malignancy but few targets have been identified and evalu-
M1A as an enzymatic target to effect downregulation of the
otential. The finding that potent pharmacologic inhibitors of
ion of both murine and primary human MLL leukemia cells,
cells, provides strong evidence for a possible therapeutic
for differentiation therapy in the MLL molecular subtype of
hibition as a therapeutic strategy more generally in myeloid
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KDM1A/LSD1 and MLL LeukemiaOne such candidate is KDM1A (also known as AOF2, LSD1,
KIAA0601, or BHC110), a flavin adenine dinucleotide (FAD)-
dependent lysine-specific demethylase with monomethyl- and
dimethyl-histone H3 lysine-4 (H3K4) and lysine-9 (H3K9)
substrate specificity (Shi et al., 2004; Metzger et al., 2005). It is
a component of both an MLL supercomplex (Nakamura et al.,
2002), which is associated with sites of active transcription,
and an ELL (elongation factor RNA polymerase II) complex,
which contains pTEFb components that interact with AF9 and
AF4, two common oncogenic fusion partners for MLL (Biswas
et al., 2011). It is also a component of complexes associated
with transcription repression, such as CoREST-HDAC, CtBP,
and NuRD (reviewed in Hou and Yu, 2010). Although KDM1A
expression has been correlated with poor prognosis in high-
risk prostate and breast cancer and poor differentiation in neuro-
blastoma (Kahl et al., 2006; Schulte et al., 2009; Lim et al., 2010),
there is little information to date as to its functional role inmyeloid
leukemia nor whether it represents a viable therapeutic target.
RESULTS
Kdm1a Is Required for theClonogenic and LSCPotential
of MLL-AF9 AML Cells
To determine whether the expression of known or candidate
histone demethylases correlates with AML LSC potential, we
analyzed microarray data sets from 23 murine MLL leukemias
with known AML colony-forming cell (AML-CFC) frequencies,
including those with high (MLL-AF9 and MLL-ENL) or low
(MLL-AF10, MLL-AF1p and MLL-GAS7) frequencies (Somer-
vaille et al., 2009). The formation of blast-like (type 1) colonies
in semi-solid culture by murine MLL-AF9 AML-CFCs directly
correlates with LSC potential (Somervaille and Cleary, 2006).
The strongest correlation of array expression values with AML-
CFC frequency was observed for Kdm1a (Figure S1A and Table
S1 available online), and this was confirmed by quantitative PCR
(Figure S1B). With the exception of MLL-AF1p AMLs, which
exhibit a more myeloproliferative morphologic phenotype than
do the other MLL subtypes (Somervaille et al., 2009), FACS-puri-
fied KIT+ cell populations, which are enriched for LSCs (Somer-
vaille and Cleary, 2006; Krivtsov et al., 2006), expressed higher
levels of Kdm1a than did their downstream KITneg progeny (Fig-
ure S1C), suggesting downregulation of expression upon LSC
differentiation. We therefore hypothesized that Kdm1a is a key
regulator of MLL LSCs.
To address this hypothesis, we generated a cohort of mice
withMLL-AF9 AML using a retroviral transduction and transplan-
tation approach (Somervaille et al., 2009) and targeted Kdm1a
for knockdown (KD) in AML cells from sick mice. Kdm1a KD
AML cells formed significantly fewer colonies in semi-solid
culture compared with cells infected with a nontargeting control
(NTC) vector (Figure 1A). The small number of Kdm1a KD colo-
nies that did form exhibited altered morphology. Compared
with controls, there was a significantly higher frequency of type
3 colonies, which contain terminally differentiatedmacrophages,
and a significantly lower frequency of type 1 colonies, which
contain poorly differentiated myeloblasts (Figures 1A and 1B).
Cytospin preparations of cells recovered at the end of culture
confirmed these observations (Figure S1D). The extent of
Kdm1a KD correlated significantly with loss of AML-CFC poten-474 Cancer Cell 21, 473–487, April 17, 2012 ª2012 Elsevier Inc.tial, both when separate targeting constructs were compared
one with another (Figure 1C) and when a single targeting
construct was used with GFP as a selectable marker and
transduced cell populations were sorted according to GFP
expression (Figures S1E–S1G). Consistent with loss of AML-
CFC potential, Kdm1a KD cells expressed lower levels of genes
associated with MLL LSC potential (Figure 1D). Annexin V
binding assays also demonstrated that some Kdm1a KD cells
underwent apoptosis, beginning at 72–96 hr (Figures S1H and
S1I). Loss of AML-CFC potential was also observed with
Kdm1a KD in murine MLL-ENL, MLL-AF10, MLL-LAF4, and
MLL-AF1p leukemia cells (Figure S1J). Forced expression of
human KDM1A, which differs by three bases to murine Kdm1a
at the locus targeted by shRNA #4, in significant part rescued
CFC potential and blocked differentiation (Figures 1E–1G).
Forced expression of hKDM1A in leukemias with lower frequen-
cies of LSC, such as those initiated by MLL-AF10 and MLL-
AF1p, did not increase AML-CFC frequency (data not shown).
To confirm Kdm1a KD AML cells were unable to function as
LSCs, we performed secondary transplantation of Kdm1a KD
or control MLL-AF9 AML cells. All mice (n = 5) receiving 2,000
control AML cells died of short latency AML, as did two of five
mice transplanted with 500 cells (Figure 1H). AML cells recov-
ered from sick mice were Mac1+Gr1+GFP+, consistent with
expression of the NTC lentiviral vector (Figure S1K). By contrast,
all mice receiving 500Kdm1aKDAML cells survived to the termi-
nation of the experiment, as did three of fivemice receiving 2,000
Kdm1a KD cells. Of the two mice that received Kdm1a KD cells
that died, cells from one could not be analyzed due to putrefac-
tion; the other died of a GFP leukemia, which expressed normal
levels of KDM1A (Figure S1K). Two further cohorts of mice were
analyzed for engraftment of GFP+ MLL-AF9 AML cells 40 days
following secondary transplant (Figure S1L). Whereas 68% ±
15% or 25% ± 17% (mean ± SEM) of bone marrow (BM) cells
were GFP+ in mice transplanted with 104 or 2.5 3 103 control
AML cells, respectively, only 0.06% ± 0.03% or 0.04% ± 0.03%
of cells were GFP+ in mice receiving Kdm1a KD cells. Together,
these data demonstrate that Kdm1a is an essential regulator of
murine MLL-AF9 LSCs and sustains the LSC potential of MLL
AML cells through prevention of differentiation and apoptosis.
KDM1A Is Required to Sustain Expression of the
MLL-AF9 Oncogenic Program
To investigate the genetic program regulated by KDM1A in
murine MLL-AF9 AML cells enriched for LSCs (Somervaille and
Cleary, 2006; Krivtsov et al., 2006), we compared the transcrip-
tome of KIT+Gr1+ control and Kdm1a KD cells using exon arrays
soon after initiation of KD (Figure 2A). Three separate samples
from two different animals were used. At this time there was no
immunophenotypic evidence of differentiation inKdm1aKD cells
(Figure 2A and data not shown).
Exonic expression values were condensed into gene level
expression summaries (Table S2), which represent the mean
expression value of the probe sets targeting the length of a given
protein coding gene. Kdm1a was the most consistently and
extensively downregulated gene in Kdm1aKDAML LSCs across
the three sample pairs, as demonstrated by a signal-to-noise
ranking metric (Figure 2B). In conventional comparative anal-
yses, many more genes were downregulated than were
Figure 1. KDM1A Is an Essential Regulator of MLL-AF9 LSC
Murine MLL-AF9 AML BM cells were infected with lentiviruses expressing shRNAs targeting Kdm1a or a nontargeting control (NTC).
(A) Bar graphs show AML-CFC frequencies of control or Kdm1a KD cells (constructs #1–#5; left) or colony types formed by control (right) or Kdm1a KD (construct
#4) cells, enumerated after six days of culture (mean ± SEM; n = 3; * indicates p% 0.05, ** indicates p% 0.01).
(B) Image shows typical type 1 or type 3 colonies.
(C) Graph shows correlation of Kdm1a KD with inhibition of CFC formation, as determined by qPCR 96 hr after KD initiation, for the five constructs tested.
(D) Relative expression of LSC-associated genes, as determined by qPCR, in Kdm1a KD cells (construct #4) compared with control cells after five days in semi-
solid culture. Error bars refer to SEM of triplicate analyses.
(E) Western blot shows KDM1A expression in murine MLL-AF9 AML cells 48 hr following initiation of Kdm1a KD (construct #4) in the presence or absence of
forced human KDM1A expression.
(F) Bar graph showsmean ± SEMAML-CFC frequencies of control andKdm1a KDmurineMLL-AF9 AML cells in the presence or absence of forced expression of
human KDM1A (n = 8; *** indicates p% 0.001). MTV, empty pMSCV vector.
(G) Representative images of cytospin preparations of AML cells recovered at the end of semi-solid culture.
(H) Survival curves of sublethally irradiated syngeneic mice transplanted with 500 (n = 5) or 2,000 (n = 5) control or Kdm1a KD (construct #4) MLL-AF9 AML cells.
See also Figure S1 and Table S1.
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KDM1A/LSD1 and MLL Leukemiaupregulated (374 genes downregulated and 63 upregulated at p
% 0.05 [paired t test] and 1.25-fold change; Figure 2C and Table
S3). False discovery rates (1,000 permutations) were 12.0% and
76.2%, respectively, confirming the significance of the downre-
gulated gene set. Genes consistently and significantly downre-
gulated across the three sample pairs upon Kdm1a KD included
leukemia-associated genes, such as Ctnnb1 and Id2, and chro-
matin regulatory genes, such as Polycomb-regulatory complex 1
(PRC1) components Bmi1, Pcgf1, Pcgf5, and Sfmbt1; NuRD
components Mta3 and Hdac2; and ING2/HDAC complex com-
ponents Ing2, Arid4a, and Hdac2. This initial analysis suggestedthat KDM1A contributes directly or indirectly to maintenance of
expression of key transcription factors and chromatin regulatory
genes in MLL-AF9 LSCs.
To identify gene sets whose co-ordinate expression was
dependent upon KDM1A, we performed gene set enrichment
analysis (GSEA; Subramanian et al., 2005). This revealed highly
significant downregulation of gene sets required for, or associ-
ated with, MLL-AF9 leukemogenesis, including an MLL LSC-
associated gene set (Somervaille et al., 2009; Figure 2D;
NES2.0; FDR 0%); the set of genes directly bound byMLL-AF9
in murine AML cells (Bernt et al., 2011; Figure 2E; NES 2.1;Cancer Cell 21, 473–487, April 17, 2012 ª2012 Elsevier Inc. 475
Figure 2. KDM1A Sustains Expression of an MLL-AF9-Associated Oncogenic Program
BM cells from mice with MLL-AF9 AML were infected with Kdm1a KD or nontargeting control lentiviruses, with GFP as a selectable marker.
(A) FACS plots show the gating strategy for sorting GFP+KIT+Gr1+ control (NTC) or Kdm1a KD cells 42 hr following lentiviral infection.
(B) Table shows the five most consistently and extensively downregulated protein coding genes, according to a signal-to-noise ranking metric.
(C) Heat map represents 374 downregulated and 63 upregulated protein coding genes differentially expressed (p% 0.05; fold changeR 1.25) between Kdm1a
KD and control samples (n = 3). Color scale indicates normalized expression values.
(D–G) GSEA plots show downregulation of (D) MLL LSC maintenance signature genes, (E) genes bound by MLL-AF9 in murine AML cells, (F) genes regulated by
MLL-AF9 in murine MLL-AF9;NrasG12D AML cells, and (G) MYC ‘‘core module’’ genes in embryonic stem cells, in Kdm1a KD MLL-AF9 LSCs versus controls (for
gene sets, see Table S5).
See also Tables S2–S6.
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KDM1A/LSD1 and MLL LeukemiaFDR 0%); the set of genes downregulated upon withdrawal of
MLL-AF9 expression in murine MLL-AF9;NrasG12D AML cells
(Zuber et al., 2011a; Figure 2F; NES 2.0; FDR 0%) and MYC476 Cancer Cell 21, 473–487, April 17, 2012 ª2012 Elsevier Inc.‘‘core module’’ genes; the set of genes bound by the combination
of MYC, MAX, MYCN, DMAP1, E2F1, E2F4, and ZFX in murine
embryonic stem cells (ESCs; Kim et al., 2010; Figure 2G; NES
Figure 3. Derepression of Polycomb and REST Target Genes and Differential Regulation of Active versus Inactive Genes in Kdm1a KD
MLL-AF9 AML cells
(A–D) GSEA plots show derepression of (A) Polycomb-related complex (PRC) module genes, (B) genes bound by PRC2 in ESCs, (C) genes bound by the PRC1
component RNF2 in ESCs, and (D) genes with a REST binding motif at their promoter in Kdm1a KDMLL-AF9 LSCs versus controls (for gene sets, see Table S5).
LE, leading edge.
(E–G) Graphs show log2 gene level array expression values (Log2 EV) versus signal-to-noise ranking metric scores (S2N score, reflecting change in expression;
Table S4) for (E) MLL LSCmaintenance signature genes, (F) genes bound by MLL-AF9, and (G) genes bound by PRC2 in ESCs. The x axis crosses at the median
expression value for all protein coding genes.
(H and I) Graphs show Log2 EV versus S2N score for (H) all 15,920 protein coding genes represented on the array that have annotated human orthologs or (I) those
with S2N scores between 3 and 3.
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KDM1A/LSD1 and MLL Leukemia2.0;FDR0%).ThesedatashowthatKDM1A is required tosustain
expression of oncogenic programs associated with MLL-AF9.
Derepression of Polycomb Targets following Kdm1a
Knockdown
In contrast to simple comparative analysis, GSEA revealed co-
ordinate upregulation of genes bound by Polycomb proteins in
ESCs. In Kdm1a KD cells, there was significant enrichment in
the set of upregulated genes of Polycomb-related complex
(PRC) module genes (Figure 3A; NES 2.0; FDR 0%; Kim et al.,
2010), which are genes co-occupied by SUZ12, EED, PHC1,and RNF2 in ESCs. Significant enrichment was also observed
when genes targeted by PRC2 (Figure 3B; NES 2.2; FDR 0%;
Lee et al., 2006; Ben-Porath et al., 2008; the set of genes co-
occupied/marked by SUZ12, EED and H3K27Me3 in human
ESCs) or the PRC1 component RNF2 (Figure 3C; NES 1.6;
FDR 0.2%; Boyer et al., 2006) were considered separately.
Many of the 279 genes in the PRC2 analysis ‘‘leading edge’’
(Figure 3B) were developmental regulators; 53 were annotated
with the Swiss-Prot/Protein Information Resource keyword
‘‘Homeobox’’ (p = 1044), with roles in the development of skel-
etal muscle, nervous tissue, pancreas, heart, limbs, and sensoryCancer Cell 21, 473–487, April 17, 2012 ª2012 Elsevier Inc. 477
Figure 4. Selective Increase in Dimethyl-H3K4 ChIPseq Signal at MLL-AF9-Bound Genes in Kdm1a KD MLL-AF9 AML Cells
(A and B) Kdm1a KD or control murine MLL-AF9 AML cells were FACS purified 42 hr following lentiviral infection, with GFP as the selectable marker, and
subjected to ChIPseq. Graphs showmean signal for (A) dimethyl-H3K4 and (B) trimethyl-H3K4 across and surroundingMLL-AF9 bound genes and non-MLL-AF9
bound genes with high, intermediate, and low level expression, in control (left panels) and KD cells (right panels). The open reading frame of each gene was
divided into ten equal segments for the analysis. Signal is defined as mean uniquely mapped reads per kilobase per million reads. * indicates p < 0.005 for
comparison of MLL-AF9 bound genes (black line) versus highly expressed non-MLL-AF9 bound genes (red line) at the same locus.
(C) Scatter plots showmean dimethyl- versus trimethyl-H3K4 signal for MLL-AF9 bound (blue dots) or non-MLL-AF9 bound (gray dots) genes with above median
array expression values in control (left panel) or knockdown (right panel) cells. Dotted lines indicate median dimethyl:trimethyl H3K4 signal ratio for non-MLL-AF9
bound genes.
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KDM1A/LSD1 and MLL Leukemiaorgans. There was also co-ordinate upregulation of genes
with promoter regions containing a RE1-silencing transcription
factor (REST)-binding motif (http://www.broadinstitute.org/
gsea; Figure 3D; NES 2.1; FDR 0%). REST recruits KDM1A
and RCOR1 (CoREST) to silence neuronal genes in nonneuro-
nal tissues by demethylation of H3K4 (Lee et al., 2005). By
contrast, there was no co-ordinate upregulation of genes asso-
ciated with terminal myeloid differentiation, as demonstrated by
GSEA using monocyte or neutrophil ‘‘fingerprint’’ gene sets or
the set of genes upregulated during phorbol ester-induced
macrophage differentiation of human THP1 MLL-AF9 AML
cells (data not shown; for gene sets, see Table S5). Thus, while
KDM1A contributes directly or indirectly to gene repression
in MLL-AF9 AML LSCs, downregulation of the oncogenic
program precedes upregulation of a myeloid differentiation
program.
Differential Response of Active versus Less-Active/
Repressed Genes
The above observations reflected more generalized, differential
consequences for active versus less-active/repressed genes
following Kdm1a KD. For example, MLL LSCmaintenance signa-
turegenes (Somervailleet al., 2009) andgenesboundbyMLL-AF9
(Bernt et al., 2011), which were co-ordinately downregulated,
almost exclusively exhibited above median array expression
values (Figures 3E and 3F). By contrast, genes targeted by
PRC2 in ESCs, which were co-ordinately upregulated, mostly ex-
hibited below median expression levels (Figure 3G). Differential
changes in expression of these discrete gene sets occurred in
concert with a more generalized shift in gene expression, with
downregulation of active genes (above median) and upregulation
of less-active/repressedgenes (belowmedian; Figures3Hand3I).
Selective Increase in Dimethyl-H3K4 ChIPseq Signal at
MLL-AF9 Bound Genes following Kdm1a Knockdown
To investigate the effects of Kdm1a KD on histone modifica-
tions, we performed chromatin immunoprecipitation, followed
by next-generation sequencing (ChIPseq), in control and
Kdm1a KD MLL-AF9 AML cells for dimethyl-H3K4 and
dimethyl-H3K9, as well as for trimethyl-H3K4 and trimethyl-
H3K9. Dimethyl-H3K4 and dimethyl-H3K9 are targeted for
demethylation by KDM1A. For each of these histone modifica-
tions, we compared the mean ChIPseq signal across and
around protein-coding genes bound by the MLL-AF9 oncopro-
tein (Bernt et al., 2011; Table S5), with the mean signal from
genes not bound by MLL-AF9 expressed at high, middle, or
low levels (Table S2). As expected, in control cells the highest
dimethyl- and trimethyl-H3K4 signal was observed surrounding
promoter regions, with signal strength related to gene expres-
sion (Figures 4A, 4B, and S2A). Following Kdm1a KD, and
consistent with localization of KDM1A in myeloid leukemia cells(D) GSEA plot shows enrichment of MLL-AF9-bound genes among protein codin
Kdm1a KD versus control cells (Table S7).
(E) Scatter plot shows log2 fold change in dimethyl:trimethyl H3K4 ratio (DH3K4 m
Kdm1a KD versus control cells plotted against their signal-to-noise metric (S2N)
(F) Box plot shows median ± 25th percentile and range of S2N scores for MLL
dimethyl:trimethyl H3K4 ratios.
See also Figure S2 and Table S7.at active promoters and enhancers (Figure S2B; Ram et al.,
2011), there was a highly significant increase in mean
dimethyl-H3K4 signal at promoters and across bodies of genes
bound by MLL-AF9 compared with other moderately or highly
expressed non-MLL-AF9-bound genes (Figure 4A). By contrast,
there was no significant increase in mean dimethyl-H3K4 signal
when the MLL LSC-associated gene set (Somervaille et al.,
2009), the set of genes downregulated upon withdrawal of
MLL-AF9 expression in murine MLL-AF9;NrasG12D AML cells
(Zuber et al., 2011a), or MYC ‘‘core module’’ genes (Kim
et al., 2010) were considered (data not shown). Indeed, mean
dimethyl-H3K4 signal decreased at moderately expressed
non-MLL-AF9 bound genes (Figure 4A, green line). There was
also no significant change in mean trimethyl-H3K4, dimethyl-
H3K9, or trimethyl-H3K9 signal in Kdm1a KD versus control
cells (Figures 4B, S2A–S2D), and there were only modest
changes in global signals for each of the marks in western
blotting analyses (Figure S2E). Thus, knockdown of the
dimethyl-H3K4 demethylase KDM1A leads to a selective in-
crease in dimethyl-H3K4 ChIPseq signal at genes bound by
the MLL-AF9 oncoprotein.
The mean ratio of dimethyl-H3K4 to trimethyl-H3K4 signal
was significantly lower in control cells at MLL-AF9-bound
genes compared with non-MLL-AF9-bound genes expressed
at above array median levels (0.54 ± 0.72 versus 0.88 ± 0.66,
respectively [mean ± SD]; p < 105; Figure 4C), due in large
part to significantly greater trimethyl-H3K4 signal across the
bodies of MLL-AF9-bound genes (Figure 4B). Following knock-
down, ratios became comparable (0.84 ± 0.59 versus 0.76 ±
0.46, respectively [mean ± SD]; p = NS; Figure 4C). The signif-
icance of the selective increase in dimethyl-H3K4 signal at
MLL-AF9-bound genes was further illustrated by GSEA (Fig-
ure 4D). MLL-AF9-bound genes cluster toward the top of
a list of protein-coding genes ranked according to fold change
in dimethyl-H3K4 marks in Kdm1a KD versus control cells
(Table S7). Increased dimethyl:trimethyl H3K4 ratio at MLL-
AF9-bound genes was associated with reduced expression
(Figures 4E and 4F). Of note, we also observed a modest but
significant excess of dimethyl- and trimethyl-H3K9 marks at
MLL-AF9-bound genes by comparison with non-MLL-AF9-
bound moderately or highly expressed genes (Figures S2C
and S2D).
Together, these data are consistent with the concept of an
epigenetic lesion in MLL leukemia (Guenther et al., 2008; Bernt
et al., 2011) and suggest that, in this context, continued expres-
sion of MLL-AF9-bound genes may be directly dependent upon
the colocalized dimethyl-H3K4 demethylase activity of KDM1A.
The LSCmaintenance orMYCmodule oncogenic programs, and
other active genes, whose expression is subordinate to the set
of MLL-AF9-bound genes, are likely indirectly dependent on
KDM1A, downstream of MLL-AF9.g genes ranked according to fold change in dimethyl-H3K4 ChIPseq signal in
e2:me3 ratio) at MLL-AF9 bound (blue dots) and unbound (gray dots) genes in
scores (reflecting change in expression; Table S4).
-AF9 bound genes with unchanged (i.e., 0.5 to 0.5) or increased (>1) log2
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Figure 5. Tranylcypromine Analogs Phenocopy
Kdm1a Knockdown
(A and B) Bar graphs show frequencies of colony types
following treatment of AML cells with the indicated
concentrations of Compounds A and B (means of three
experiments and estimated biologic IC50 for type 1 colony
formation are shown).
(C) Representative images of murine MLL-AF9 AML
colonies after six days in semi-solid culture with the
indicated type and concentration of inhibitor or vehicle.
(D) Relative expression of LSC-associated genes, as
determined by qPCR, in murine MLL-AF9 AML cells
treated with the indicated concentrations of Compound B
compared with vehicle-treated cells after five days in
semi-solid culture. Error bars refer to SEM of triplicate
analyses.
See also Figure S3.
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KDM1A/LSD1 and MLL LeukemiaPharmacologic Inhibition of KDM1A Phenocopies
Knockdown in Murine and Primary Human MLL AML
Cells
Given these data, Kdm1a represents an attractive therapeutic
target in MLL leukemia. KDM1A is inhibited in vitro at an IC50
of 20 mM by the monoamine oxidase inhibitor tranylcypromine
(TCP) (Hou and Yu, 2010), which is used in the treatment of
depression. We treated murine MLL-AF9 AML cells, human
THP1 cells (which harbor a t(9;11) translocation, the cytogenetic
hallmark of MLL-AF9), and primary human MLL leukemia cells
with TCP. At a concentration close to the IC50 for KDM1A, TCP
induced loss of clonogenic potential and induction of differenti-
ation in murine (Figures S3A and S3B), human THP1 (Figures
S3C and 3SD), and primary humanMLL leukemic blasts (Figures
S3E and S3F), as demonstrated by colony morphology and
examination of cytospin preparations. Consistent with the deple-
tion of type 1 myeloblast colonies by TCP treatment (Figure S3A)
and our previous observation that MLL-AF9 AML-CFCs have
LSC potential (Somervaille and Cleary, 2006), there was a signif-
icant delay in initiation of secondary AML by murine MLL-AF9
AML cells that had been incubated in vitro for five days with
25 mM TCP versus vehicle-treated control cells (Figure S3G).
In view of its lack of potency and selectivity, tranylcypromine is
likely to be of limited use in the clinic. We therefore synthesized
two analogs of tranylcypromine reported to be more potent
and selective inhibitors of KDM1A (Guibourt, 2010): trans-N-
((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2-phenylcyclopro-
pan-1-amine (hereafter Compound A) and trans-N-((2-methoxy-
pyridin-3-yl)methyl)-2-phenylcyclopropan-1-amine (hereafter
Compound B; Figure S3H). These compounds inhibited the
enzymatic activity of KDM1A with IC50s of 670 and 98 nM,
respectively, versus 15.7 mM for tranylcypromine using the
same assay (Figures S3I–3K). Treatment of murine MLL-AF9
AML cells with Compounds A and B phenocopied both Kdm1a480 Cancer Cell 21, 473–487, April 17, 2012 ª2012 Elsevier Inc.KD and TCP treatment, also at concentrations
close to their IC50s for KDM1A (Figures 5A–5C;
versus 8 mM for TCP; Figure S3A). Thus, the
tested TCP analogs exhibited 23- and 57-fold
greater biological potencies, respectively, than
did TCP in a similar cell setting. As with
Kdm1a KD, MLL-AF9 AML cells treated withCompound B also exhibited reduced expression of genes
associated with LSC potential (Figure 5D), in particular core
components of the LSC maintenance signature (Somervaille
et al., 2009).
Next, we tested fresh cells from a patient newly diagnosed
with high-count AML associated with a t(9;11) translocation,
the hallmark of MLL-AF9 AML. As for murine MLL-AF9 cells,
Compounds A and B inhibited colony formation of human
MLL-AF9 AML cells and promoted differentiation in a dose-
dependent manner (Figures 6A and 6B), with the effect being
observed at biologic IC50s of 270 and 50 nM, respectively.
Following ten days of semi-solid culture, Compound B treatment
induced both morphologic (Figure 6C) and immunophenotypic
differentiation (Figures 6D and S4A–S4C), the latter demon-
strated by reduction in the proportion of AML cells with an imma-
ture immunophenotype (CD34+CD14CD86CD36). CD14,
CD86, and CD36 are upregulated during monocyte/macrophage
differentiation. A similar phenotype was observed following
Kdm1a KD in primary AML cells from a patient with a t(6;11)
translocation, the cytogenetic hallmark of MLL-AF6 (Figures
S4D and S4E). We also tested the effect of Compound B on
the clonogenic potential in semi-solid culture of a panel of AML
cell lines reflecting a range of molecular subtypes (Figure 6E).
Whereas dose-dependent inhibition of colony formation was
observed for most lines tested, the most striking inhibition was
observed for MLL fusion oncogene-associated lines.
KDM1A Knockdown or Inhibition Spares the Clonogenic
Potential of Normal Myeloid, but Not Erythroid,
Progenitor Cells
Knockdown or inhibition of KDM1A in primary normal human
CD34+ hematopoietic cells significantly reduced the frequency
of CFCs, predominantly due to loss of erythroid burst-forming
units (BFU-E; Figures 7A–7E). The clonogenic potential of
Figure 6. Tranylcypromine Analogs Phenocopy Kdm1a Knockdown in Human MLL Leukemia Cells
(A) Bar graph shows CFC frequencies of primary humanMLL-AF9 AML cells after ten days in semi-solid culture with the indicated concentrations of Compounds
A and B. Representative images show (B) primary human MLL-AF9 AML colonies (sample BB160) and (C) cytospin preparations of cells recovered at the end of
semi-solid culture. B, blast; M, macrophage.
(D) Bar graph shows frequency of CD34+Lin (CD14CD36CD86) primary human MLL-AF9 AML cells at the end of semi-solid culture in the presence of the
indicated concentration of KDM1A inhibitor, as determined by FACS analysis.
(E) Bar graph showsmean±SEMCFC frequency in semi-solid culture of the indicated humanAMLcell lines following treatmentwithCompoundBor vehicle (n =3).
See also Figure S4.
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KDM1A/LSD1 and MLL Leukemiamyeloid lineage colonies was preserved, although an increase in
CFU-Mwas noted in Compound B-treated cells. For knockdown
experiments, two different lentivirally expressed shRNAs, which
reduced KDM1A expression to 31% (#1) or 38% (#2), respec-
tively, were used. FACS analysis of TCP-treated CD34+ cells
after two weeks of culture revealed a significant reduction in
the proportion of cells expressing high levels of glycophorin A
(Figure 7F), a marker upregulated in the late stages of human
erythroid differentiation. We found similar sparing of myeloid
colony-forming potential in experiments using murine KIT+ BM
HSPCs cultured in conditions supporting myeloid development
(data not shown).
Selective In Vivo Activity of KDM1A Inhibition versus
MLL-AF9 Leukemia
To assess whether KDM1A inhibition also selectively targets
MLL AML cells in vivo, we transplanted CD45.2+ MLL-AF9murine AML cells into sublethally irradiated CD45.1+ congenic
recipients and treated mice with DMSO vehicle, 10 mg/kg
Compound B or 25 mg/kg Compound B twice daily by intraper-
itoneal injection according to the indicated schedule (Figure 8A).
Plasma levels of CompoundBmeasured one hour after a dose of
50 mg/kg IP were 2.0 ± 0.2 mM (n = 3), as determined by liquid
chromatography-mass spectrometry. Complete blood counts
and blood smears performed at the end of treatment in
vehicle-treated mice demonstrated substantial leukemic leuko-
cytosis with circulating blasts and leukemic myelomonocytic
cells, modest anemia, and thrombocytopenia, consistent with
incipient AML (Figures 8B and 8C). By contrast, mice treated
with KDM1A inhibitor lacked evidence of circulating AML cells
but were instead significantly more anemic and thrombocyto-
penic than were vehicle-treated controls and exhibited circu-
lating nucleated erythroid precursors and polychromasia con-
sistent with the degree of anemia (mean ± SEM hemoglobinCancer Cell 21, 473–487, April 17, 2012 ª2012 Elsevier Inc. 481
Figure 7. Preservation of Normal Myeloid, but Not Erythroid, Colonies following KDM1A Knockdown or Inhibition
(A and B) Bar graphs show CFC frequencies and colony types of normal human CD34+ cells (A) infected with nontargeting control (NTC) or KDM1A-targeting
(#1 and #2) lentiviruses, (B) treated with tranylcypromine 25 mM or (C) treated with the indicated concentrations of Compound B (mean ± SEM; n = 3; * indicates
p% 0.05). Note sample-to-sample variability in BFU-E frequency in primary patient material.
(D) Representative images show colonies formed in the presence of the indicated concentrations of Compound B.
(E) Bar graph shows frequency of BFU-E arising from normal human CD34+ HSPCs cultured in the indicated concentration of KDM1A inhibitor.
(F) Bar graph shows the percentage of glycophorin A+ cells at the end of ten days in semi-solid culture of CD34+ cells in the presence of tranylcypromine or vehicle
(mean ± SEM; n = 3; * indicates p% 0.05). BFU-E, burst-forming unit erythroid; CFU-GM/G, colony-forming unit granulocyte/macrophage or colony-forming unit
granulocyte; CFU-M, colony-forming unit macrophage.
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KDM1A/LSD1 and MLL Leukemia5.0 ± 0.7 g/dl for mice receiving the 25 mg/kg dose vs. 9.0 ± 0.4
g/dl for vehicle-treated mice; p < 0.001; n = 6; mean ± SEM
platelet count 89 ± 9 3 109/l for mice receiving the 25 mg/kg
dose vs. 592 ± 55 3 109/l for vehicle-treated mice; p < 0.001;
n = 6; Figures 8B and 8C). Thus, treatment of mice with
KDM1A inhibitor completely blocked progression of MLL-AF9
leukemia into the circulation.
Consistent with this observation, analysis of AML cells aspi-
rated from BM at the end of the treatment period showed
a dose-dependent, significant reduction in both expression of
KIT, which marks MLL-AF9 LSCs, and the frequency of AML-
CFCs in FACS-purified CD45.2+ AML cells (Figures 8D–8G).
There was also a dose-dependent trend toward reduced donor:-
recipient chimerism (Figure S5A). By contrast, neither KIT482 Cancer Cell 21, 473–487, April 17, 2012 ª2012 Elsevier Inc.expression nor clonogenic potential of FACS-purified residual
CD45.1+ normal hematopoietic cells were impacted by treat-
ment with KDM1A inhibitor (Figures 8E and 8H). Furthermore,
FACS-purified CD45.1+KIT+Gr1 normal cells from KDM1A
inhibitor-treated mice retained lympho-myeloid repopulating
activity in secondary transplantation assays (Figures 8I–8K).
Although there was a trend toward prolonged survival for
leukemic mice treated with Compound B (Figure S5B), a number
of mice died of drug-induced anemia rather than leukemia, thus
confounding interpretation of survival as an endpoint. Finally, we
treated immune-deficient mice xenografted with primary human
MLL-AF6 AML cells with Compound B. By comparison, with
vehicle-treated mice, a higher proportion of human AML cells
in animals treated with KDM1A inhibitor expressed the
Cancer Cell
KDM1A/LSD1 and MLL Leukemiamonocyte/macrophage differentiation markers CD36 and CD86,
and fewer cells expressed an immature CD34+CD36CD86 im-
munophenotype (Figure S5C).
Together, these in vitro and in vivo data demonstrate that
different types of normal and malignant hematopoietic cells
exhibit differential sensitivities to pharmacologic KDM1A inhibi-
tion. The relative sensitivity ofMLL-AF9AMLcells by comparison
with normal HSPCs suggests a significant therapeutic window.
Discussion
Our genetic and pharmacologic data using murine models and
primary human AML cells demonstrate that KDM1A is required
to sustain the expression of the MLL-AF9-associated oncogenic
program, thus maintaining the oncogenic potential of MLL-AF9
LSCs. They also highlight the enzyme as a potential therapeutic
target in MLL leukemias, which is of importance given the devel-
opment of KDM1A inhibitors by the pharmaceutical industry
(Guibourt, 2010). The progeny of individually isolated blast-like
(type 1) MLL-AF9 AML colonies (Figure 1B) reliably initiate AML
in secondarily transplanted recipients, demonstrating the iden-
tity of the parental CFC as a cell with LSC potential (Somervaille
and Cleary, 2006). Thus, our observation that Kdm1a KD or
inhibition resulted in loss of AML-CFCs, with induction of differ-
entiation, was highly significant, as was the observation that
Kdm1a KD MLL-AF9 AML cells fail to initiate leukemia in
secondary transplantation experiments. Although a direct link
between in vitro clonogenic potential and LSC potential in
primary human MLL AML has not been proven, it is nevertheless
of note that we found frequencies of clonogenic cells in patient
samples ranging from 1%–9%, not dissimilar to those found in
the murine model.
KDM1A Sustains Expression of the MLL-AF9 Oncogenic
Program
Recent studies have associated the expression of defined gene
sets with the oncogenic potential of MLL LSCs (Somervaille
et al., 2009; Kim et al., 2010; Bernt et al., 2011; Zuber et al.,
2011a). At an early time point following initiation of Kdm1a KD
in murine MLL-AF9 LSCs, these gene sets were co-ordinately
downregulated, and this occurred prior to upregulation of gene
sets or cell surface markers associated with terminal myeloid
differentiation or the onset of apoptosis in some cells. Loss of
clonogenic potential with induction of differentiation and
apoptosis is a phenotype very similar to that observed upon
tamoxifen withdrawal from murine BM HSPCs immortalized by
an MLL-ENL estrogen receptor fusion (Somervaille et al.,
2009). This observation suggests the possibility that KDM1A
might have a close physical or functional interaction with MLL-
AF9, acting as an essential oncogenic cofactor to maintain
transformation.
Two lines of evidence suggest this may be the case. First,
KDM1A is a member of an ELL complex identified in 293 cells
(Biswas et al., 2011), which includes pTEFb members CDK9
and CCNT1 and the MLL oncogenic fusion partners AFF1 (also
known as AF4) and AFF4 (also known as AF5q). ELL, CDK9,
CCNT1, AFF1, and AFF4 associate with one another either in
a static ‘‘super-elongation complex’’ (SEC) or in a dynamic set
of higher order complexes that interact with MLL oncogenic
fusions, including MLL-AF9 (Lin et al., 2010; Yokoyama et al.,2010). Such interactions may serve to recruit KDM1A to genomic
loci bound by MLL oncoproteins. The second piece of evidence
arises from our ChIP-sequencing analyses, which suggest a
‘‘footprint’’ of KDM1A activity at genomic loci bound by MLL-
AF9. While KDM1A binds promiscuously across the genome,
especially at active promoters and enhancers (Ram et al.,
2011), following Kdm1a KD we observed a highly significant
and selective increase in dimethyl-H3K4 ChIPseq signal at
genes bound by the MLL-AF9 oncoprotein (Bernt et al., 2011),
which was associated with co-ordinate downregulation of the
same gene set. Dimethyl-H3K4 is a demethylation target for
KDM1A. Of note, global changes in ChIPseq signals were only
observed for the dimethyl-H3K4 mark; a global change in the
pattern of histone modifications at the gene sets analyzed was
not observed for the other marks investigated, including
dimethyl-H3K9, which is also a demethylation target of
KDM1A. Thus, the only histonemodification that exhibited signif-
icant change at MLL-AF9-bound genes following Kdm1a KD is
an enzymatic target of KDM1A.
This observation was unexpected because the dimethyl-H3K4
mark has been considered to be associated with active tran-
scription and its removal by KDM1A has been considered to
be associated with transcription repression. Examples of the
repressive function of KDM1A include its recruitment with
RCOR1 (CoREST) by REST to silence neuronal genes in non-
neuronal cells (Lee et al., 2005), its recruitment by ZEB1 to the
Gh promoter to suppress Gh expression in pituitary lactotrophs
(Wang et al., 2007), and its recruitment by GFI1 (Saleque et al.,
2007) or TAL1 (Hu et al., 2009) to their respective target genes
in early erythroid development. KDM1A is also an established
transcription activator, although in the context of demethylation
of the repression-associated dimethyl-H3K9 mark. For example,
it demethylates dimethyl-H3K9 to facilitate androgen- or
estrogen-dependent transcription in prostate or breast cancer
cells, respectively, by opposing the activity of H3K9methyltrans-
ferases (Metzger et al., 2005; Garcia-Bassets et al., 2007). Like-
wise, in development, KDM1A is required for activation of Gh
transcription in pituitary precursor cells (Wang et al., 2007). Our
observations in MLL-AF9 AML cells suggest a role for KDM1A
in the context of the epigenetic lesion associated with MLL
leukemia. This lesion is characterized by an abnormal extent
and distribution of the elongation-associated dimethyl-H3K79
mark and the transcription initiation-associated trimethyl-H3K4
mark at genes bound byMLL oncoproteins, as well asmistarget-
ing of elongation factors, such as MLLT1 (also known as ENL;
Guenther et al., 2008; Bernt et al., 2011). In keeping with
Guenther et al. (2008), we also observed an excess of tri-
methyl-H3K4 marks upstream of the promoter and across the
bodies of genes bound by MLL-AF9.
It was of note that in control MLL-AF9 AML cells the ratio of
dimethyl:trimethyl H3K4 marks at MLL-AF9-bound genes was
significantly lower than that of non-MLL-AF9-bound genes ex-
pressed at similar levels, in large part due to comparatively
higher levels of trimethyl-H3K4. Ratios became similar following
Kdm1a KD. Our data are consistent with a model in which
KDM1A acts at MLL-AF9-bound genes to maintain low levels
of dimethyl- relative to trimethyl-H3K4, a chromatin state
presumably permissive for levels of transcription required for
oncogenic transformation. This raises the question as to howCancer Cell 21, 473–487, April 17, 2012 ª2012 Elsevier Inc. 483
Figure 8. Selective In Vivo Efficacy of KDM1A Inhibition versus MLL-AF9 AML Cells
(A) Image shows experimental plan.
(B) Bar chart showsmean ± SEMhemoglobin (Hb), total white cell count (TWCC), nucleated red blood cell count (nRBC), and platelet count (Plt) in complete blood
counts frommice after 12 days of treatment with DMSO vehicle or Compound B at the indicated dose (n = 6 for each cohort). * indicates p < 0.01 for values from
KDM1A inhibitor-treated mice compared with vehicle-treated controls. Blood count values from an untreated normal adult C57BL/6 mouse are shown for
comparison.
(C) Bar chart shows mean ± SEM leukocyte manual differential counts in blood smears from vehicle- and KDM1A inhibitor-treated mice (n = 6 for each cohort).
Values from an untreated normal adult C57BL/6 mouse are shown for comparison. Maturing, maturing leukemic myelomonocytic cells; Neuts, neutrophils,
including leukemic neutrophils; Lymphs, lymphocytes; Monos, monocytes; Eos, eosinophils.
(D) Representative FACS plot shows chimerism of CD45.1+ normal recipient hematopoietic cells (A, Recipient normal) and CD45.2+ AML cells (B, Donor AML) in
a BM aspirate sample taken on day 20 post-transplant.
(E) Bar graph shows mean ± SEM percentage of CD45.1+ normal recipient or CD45.2+ AML cells co-expressing KIT. * indicates p < 0.01 for comparison of
vehicle-treated versus Compound B-treated mice (n = 6).
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KDM1A/LSD1 and MLL Leukemiaaccumulation of dimethyl-H3K4 marks might be inhibitory. It is
clear from work in yeast that dimethyl-H3K4 is a functionally
distinct modification and not simply a metabolic intermediate
between monomethyl- and trimethyl-H3K4. It serves as a plat-
form for recruitment of a Set3 complex that contains histone
deacetylase activity, which reduces acetylation toward the 50
end of genes to suppress transcription from cryptic internal
promoters (Kim and Buratowski, 2009). Furthermore, chromatin
state maps of the genome indicate that increased ratios of dime-
thyl:trimethyl H3K4 are observed at poised or weakly active
promoters by comparison with fully activated promoters (Ernst
et al., 2011). Thus, accumulation of dimethyl-H3K4 marks at
MLL oncoprotein-bound genes may enable locoregional binding
of complexes that repress transcription, leading to downregula-
tion of genes bound by MLL-AF9. Reduced expression of other
actively expressed genes, including subordinate oncogenic
programs, such as the LSC maintenance program and MYC
module, and increased expression of Polycomb-bound genes,
is likely an indirect effect of Kdm1a KD, downstream of the set
of genes bound by MLL-AF9, because we did not observe co-
ordinate changes in histone methylation status at these genomic
loci. With regard to Polycomb bound genes, for example, among
those most highly downregulated upon Kdm1a KD were genes
coding for components of PRC1, including Bmi1, which is
required for stable maintenance of transcriptionally repressed
states.
KDM1A as a Therapeutic Target in Leukemia
KDM1A has been suggested as a therapeutic target in cancer
because of its high-level expression in poor-risk prostate adeno-
carcinoma (Kahl et al., 2006), poorly differentiated neuroblas-
toma (Schulte et al., 2009), and high-grade ER-negative breast
cancer (Lim et al., 2010). Our data suggest a therapeutic role
for KDM1A inhibition in leukemias associated with expression
of MLL fusion oncoproteins. This is demonstrated by the use
of potent KDM1A inhibitors selectively to induce loss of clono-
genic potential and induction of differentiation in both murine
and primary human MLL leukemia cells, both in vitro and in vivo.
KDM1A inhibitor treatment of mice engrafted with congenic
MLL-AF9 AML cells prevented progression of AML cells into
the circulation, downregulated expression of the LSC marker
KIT, and reduced the frequency of AML cells with clonogenic
potential. Similarly, it also induced immunophenotypic differenti-
ation of xenografted primary human MLL-AF6 cells. By contrast,
normal HSPCs were spared as demonstrated by unchanged
expression of KIT, unchanged clonogenic potential in semi-solid
culture, and a retained capacity to provide lympho-myeloid(F) Representative FACSplots show expression of KIT and themonocyte/macroph
with the vehicle (upper panel) or 25 mg/kg Compound B (lower panel).
(G) Bar graph shows mean ± SEM AML-CFC frequency in CD45.2+ MLL-AF9 AM
(H) Bar graph showsmean ± SEMCFC frequency, and colony type, in normal CD4
(for G and H, * indicates p < 0.01 for comparison of vehicle-treated versus Com
colony-forming unit granulocyte/macrophage; CFU-M, colony-forming unit macr
(I) FACS plot shows donor:recipient chimerism in a BM aspirate 21 days followin
mice treated with Compound B, into a sublethally irradiated normal CD45.2+ con
(J) Graph shows percentage donor (CD45.1+) chimerism in BM aspirates for each
mice receiving a 25mg/kg dose; d indicates cells were from mice receiving a 10
(K) Graph indicates percentage of donor engrafted cells positive for B-lineage (B
See also Figure S5.reconstitution in secondary transplant experiments. KDM1A
inhibition in congenic transplant recipients also resulted in a trend
toward prolonged survival, although survival curves were con-
founded by treated mice dying as a result of drug-induced
anemia. The effect of KDM1A inhibition on erythropoiesis was
predicted by our in vitro studies, which showed a selective loss
of BFU-E activity in normal human CD34+ cells following both
Kdm1a KD and inhibition. Together, these data point to a signifi-
cant potential therapeutic window for the use of KDM1A inhibi-
tors in the MLL molecular subtype of AML.
Such differential consequences for different normal andmalig-
nant hematopoietic cell types are consistent with a previous
study using murine cell lines; Kdm1a KD impaired DMSO-
induced erythroid differentiation of MEL cells and phorbol
ester-induced megakaryocytic differentiation of L8057 cells but
induced granulocytic differentiation of 32D.4 cells (Saleque
et al., 2007). Thus, KDM1A depletion or inhibition has differing
consequences for different cellular subtypes.
How might KDM1A inhibitors be used therapeutically? Induc-
tion of differentiation of leukemic blasts using all-trans retinoic
acid (ATRA) is standard therapy in one subtype of AML, acute
promyelocytic leukemia (APML). However, whereas ATRA
alone may induce remission, it is insufficient for cure and con-
comitant treatment with anthracyline or arsenic trioxide is re-
quired (Sanz and Lo-Coco, 2011). Indeed single-agent therapy
in AML is rarely, if ever, curative. One option may be the combi-
nation of KDM1A inhibition with chemotherapy, as has been
historically effective for APML and ATRA. Alternatives might
include single agent maintenance therapy or combination
therapy with histone deacetylase (HDAC) inhibitors, because
KDM1A inhibition sensitizes breast cancer and glioblastoma
cells to HDAC inhibitor-induced cell cycle arrest or apoptosis
(Singh et al., 2011; Huang et al., 2012). Anemia or thrombocy-
topenia associated with therapy could be managed by trans-
fusion. KDM1A inhibitors may be also of value in certain myelo-
proliferative disorders.
Examination of a web-based repository of microarray data
from primary human AML samples (http://www.oncomine.org)
shows that KDM1A is expressed at comparable levels in
MLL-rearranged leukemias to those in other molecular sub-
types. Although our human cell line data suggest that MLL
oncoprotein leukemias are selectively sensitive to KDM1A inhi-
bition by comparison with other molecular subtypes of AML,
dose-dependent inhibition of clonogenic potential was also
observed for other lines, for example, NB4 cells and Kasumi1
cells (associated with PML-RARA and RUNX1-RUNX1T1, re-
spectively). This suggests the possibility that KDM1A inhibitionage differentiationmarker F4/80 in AML cells in BMaspirates frommice treated
L cells, as determined by semi-solid culture.
5.1+ cells FACS purified fromBMaspirates, as determined by semi-solid culture
pound B-treated mice [n = 6]). BFU-E, burst-forming unit erythroid; CFU-GM,
ophage.
g transplantation of 1,000 normal CD45.1+KIT+Gr1+ cells, FACS purified from
genic recipient.
of the five recipients transplanted with 1,000 cells (x indicates cells were from
mg/kg dose).
220) or myeloid lineage (Mac1) markers.
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KDM1A/LSD1 and MLL Leukemiamay be a useful therapeutic strategy in other types of myeloid
malignancy. Consistent with this, KDM1A is among the 5%
most highly expressed genes in microarray data sets from
prospectively purified immunophenotypic LSCs from a variety
of distinct AML subtypes (data extracted from Goardon et al.,
2011).
In summary, our identification of KDM1A as a candidate ther-
apeutic target in the MLL translocated subtype of AML adds to
recent studies suggesting new approaches to treat this disease,
including inhibition of the DOT1L H3K79 histone methyltransfer-
ase (Bernt et al., 2011) and the bromodomain protein BRD4
(Zuber et al., 2011b; Dawson et al., 2011). Our data mandate
further studies of the effects of KDM1A inhibition in other
subtypes of myeloid malignancy, evaluation of combination
therapies and clinical trials in AML of KDM1A inhibitors in devel-
opment by the pharmaceutical industry.
EXPERIMENTAL PROCEDURES
Vectors, Reagents, Cell Lines, Chemicals, and Antibodies
Details of retroviral and lentiviral vectors, cell lines, chemicals, FACS, western
blotting, or chromatin immunoprecipitation antibodies are in the Supplemental
Experimental Procedures. Tranylcypromine analogs trans-N-[1-(2,3-dihydro-
1,4-benzodioxin-6-yl)ethyl]-2-phenylcyclopropan-1-amine (Compound A)
and trans-N-[(2-methoxypyridin-3-yl)methyl]-2-phenylcyclopropan-1-amine
(Compound B) were synthesized in house, as described in Guibourt (2010).
Chromatin Immunoprecipitation and Next-Generation Sequencing
Chromatin immunoprecipitation (ChIP) was performed using a Red ChIP Kit
(Diagenode, Liege, Belgium) in accordance with the manufacturer’s instruc-
tions. Details of shearing, ChIPseq library preparation, next-generation
sequencing, and bioinformatics analysis are in the Supplemental Experimental
Procedures. ChIPseq BED files and raw data files are available at http://www.
ncbi.nlm.nih.gov/geo/ under the accession number GSE36348.
Flow Cytometry
FACS analyses were performed using an LSR Model II flow cytometer (BD
Biosciences, Oxford, UK). Cell sorting experiments were performed using
either an Influx or a FACS Aria flow cytometer (both from BD Biosciences).
Mice and Murine Experiments
Experiments were approved by the Paterson Institute’s Animal Ethics
Committee and performed under a project license issued by the United
Kingdom Home Office, in keeping with the Home Office Animal Scientific
Procedures Act, 1986. C57BL/6 (CD45.2+) mice were purchased from Harlan
(Shardlow, UK). B6.SJL-Ptprca Pepcb/BoyJ (CD45.1+) and NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ mice were purchased from Jackson Laboratories (Bar Harbor,
ME, USA) and bred in house. Details of experimental initiation of murine
MLL-AF9 leukemia (both primary and secondary), lentiviral infection of cryo-
preserved AML cells, and clonogenic assays of normal and leukemic cells
are in the Supplemental Experimental Procedures.
Human Tissue and Experiments
Use of human tissue was in compliance with the ethical and legal framework of
the Human Tissue Act, 2004. Normal human CD34+ mobilized HSPCs surplus
to requirements were from patients undergoing chemotherapy and autologous
transplantation for lymphoma and myeloma. Their use was authorized by the
Salford and Trafford Research Ethics Committee and, where possible,
following the written informed consent of donors. Primary human AML blasts
were from Manchester Cancer Research Centre’s Tissue Biobank (instituted
with approval of the South Manchester Research Ethics Committee); their
use was authorized following ethical review by the Tissue Biobank’s scientific
sub-committee. Written informed consent was obtained for all samples
donated to the Biobank. Details of lentiviral infection protocols and clonogenic
assays are in the Supplemental Experimental Procedures.486 Cancer Cell 21, 473–487, April 17, 2012 ª2012 Elsevier Inc.RNA Extraction, Quantitative PCR, Microarray Hybridization, and
Data Analysis
Details are in the Supplemental Experimental Procedures. Exon array CEL files
are available at http://www.ncbi.nlm.nih.gov/geo/ under the accession
number GSE36348.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, Supplemental Experimental
Procedures, and seven tables and can be found with this article online at
doi:10.1016/j.ccr.2012.03.014.
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